Pharmacology | Research Interests

Name	Email	PhD Program
Lanfersieck, Julia EMAIL	PHD PROGRAM RESEARCH INTEREST Cell Biology, Neurobiology, Pharmacology	“I am most interested in investigating the cellular and molecular mechanisms related to neurodegenerative diseases and aging, specifically in Alzheimer’s disease and dementia. I hope to broadly contribute to the questions of how AD develops and how we can treat/prevent its onset.”
Lorenz, Eva EMAIL	PHD PROGRAM RESEARCH INTEREST Behavior, Neurobiology, Pharmacology	“I hope to elucidate specific neural pathways underlying drug dependence and developing potential pharmacological targets for alleviating dependence, withdrawal, relapse from drugs.”
Lee, Craig WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Pharmaceutical Sciences RESEARCH INTEREST Cardiovascular Disease, Genetics, Metabolism, Pharmacology, Translational Medicine	Craig Lee, Pharm.D, Ph.D. is a professor in the UNC Eshelman School of Pharmacy’s Division of Pharmacotherapy and Experimental Therapeutics (DPET). A key aspect of DPET’s mission is to optimize drug therapy through translating experimental and clinical pharmacology discoveries into precision medicine and accelerating application of these discoveries to improve patient care. Dr. Lee is trained as a clinical/translational pharmaceutical scientist with expertise in cytochrome P450 metabolism, cardiovascular experimental therapeutics, and precision medicine/pharmacogenomics. He is an active member of the UNC McAllister Heart Institute and UNC Program for Precision Medicine in Healthcare, and has an adjunct faculty appointment in the UNC School of Medicine’s Division of Cardiology. The overall objective of Dr. Lee’s research program is to improve the understanding of the central mechanisms underlying inter-individual variability in drug response as a means to develop novel therapeutic strategies that will improve public health. A major scientific focus of the Lee laboratory is the metabolism of drugs and eicosanoids by the cytochromes P450 enzyme system. The major therapeutic area of application of their research is cardiovascular and metabolic disease. The Lee laboratory seeks to identify and elucidate the key factors that exacerbate inter-individual variability in the metabolism of and response to drugs currently on the market, and determine whether implementation of genomic and biomarker-guided drug selection and dosing strategies can reduce this variability in metabolism and response and improve patient outcomes. The Lee laboratory also seeks to develop a thorough understanding of how cytochrome P450-derived eicosanoids (bioactive lipid mediators of arachidonic acid) regulate hepatic and extra-hepatic inflammatory responses, and determine whether modulation of this pathway will serve as an effective anti-inflammatory and end-organ protective therapeutic strategy for cardiovascular and metabolic disease. Using genomics and biomarkers, the lab seeks to translate their preclinical discoveries into humans and determine which subsets of the population may be most likely to respond to the therapeutic strategies under evaluation in the laboratory. The Lee laboratory is a highly collaborative and translational research program that integrates mechanistically-driven rodent and cell-based preclinical models with observational and interventional clinical studies. They have received funding from the National Institutes of Health and American Heart Association, authored over 100 manuscripts and over 100 abstracts in the areas of cytochromes P450, eicosanoid and drug metabolism, pharmacogenomics, and experimental therapeutics. Dr. Lee has served as the major research advisor for over 40 graduate students, post-doctoral fellows, and professional students.
Rowe-Conlon, Sarah WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Microbiology & Immunology RESEARCH INTEREST Antibiotics/Antivirals, Bacteriology, Diabetes, Drug Delivery, Drug Discovery, Pathogenesis & Infection, Pharmacology, Translational Medicine	My lab studies recalcitrant bacterial infections and antibiotic treatment failure. Focusing on bacteremia and wound infection, we utilize a range of in vitro, tissue culture and mouse models to understand the precise nature of treatment failure and exploit this knowledge to modulate antibiotic activity in the host environment. My long-term goal is to bring improved therapeutic strategies to the bedside.
Williams, Morika WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Neuroscience, Pathobiology & Translational Science RESEARCH INTEREST Behavior, Neurobiology, Pharmacology, Physiology, Translational Medicine	Early life and adult pain can have drastic effects on neurodevelopment and overall quality of life. In the Williams’ Pain, Aging, and Interdisciplinary Neurobehavioral (P.A.I.N.) Lab, our research focuses on behavioral neuroscience and the mechanisms of neurobiology and neurophysiology of pain processing, with a special emphasis on the neonatal. The ultimate research goal is to better understand, recognize, and alleviate pain in the newborn to improve the quality of life in adulthood by uncovering new assessment tools and interventional strategies. Our research interests include the mechanisms of neurobiology and neurophysiology of pain processing, neonatal pain, chronic pain, neurobehavior, osteoarthritis, translational medicine, anesthesia/analgesics, and evoked and non-evoked pain assessment tools. The P.A.I.N. Lab has both pre-clinical and clinical studies to help close the gap in translation.
Brunk, Elizabeth WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Bioinformatics & Computational Biology, Chemistry, Pharmacology RESEARCH INTEREST Biochemistry, Bioinformatics, Biophysics, Cancer Biology, Computational Biology, Genomics, Pharmacology, Structural Biology, Systems Biology, Translational Medicine	A growing body of work in the biomedical sciences generates and analyzes omics data; our lab’s work contributes to these efforts by focusing on the integration of different omics data types to bring mechanistic insights to the multi-scale nature of cellular processes. The focus of our research is on developing systems genomics approaches to study the impact of genomic variation on genome function. We have used this focus to study genetic and molecular variation in both natural and engineered cellular systems and approach these topics through the lens of computational biology, machine learning and advanced omics data integration. More specifically, we create methods to reveal functional relationships across genomics, transcriptomics, ribosome profiling, proteomics, structural genomics, metabolomics and phenotype variability data. Our integrative omics methods improve understanding of how cells achieve regulation at multiple scales of complexity and link to genetic and molecular variants that influence these processes. Ultimately, the goal of our research is advancing the analysis of high-throughput omics technologies to empower patient care and clinical trial selections. To this end, we are developing integrative methods to improve mutation panels by selecting more informative genetic and molecular biomarkers that match disease relevance.
Merker, Jason WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Pathobiology & Translational Science RESEARCH INTEREST Bioinformatics, Cancer Biology, Genomics, Pharmacology, Translational Medicine	Our laboratory is focused on translating novel molecular biomarkers into clinical oncology practice, with the overarching goal of improving the care and survival of patients with cancer. Our group is highly collaborative and applies genomic, genetic, bioinformatic, informatic, statistical, and molecular approaches. Current projects in the laboratory include: Correlative genomic testing to support clinical trials Expanded clinical applications of RNA sequencing Development and application of cell-free circulating tumor nucleic acid assays
Walsh, Jessica WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Neuroscience, Pharmacology RESEARCH INTEREST Behavior, Neurobiology, Pharmacology, Physiology, Translational Medicine	Social behavior is composed of a variety of distinct forms of interactions and is fundamental to survival. Several neural circuits must act in concert to allow for such complex behavior to occur and perturbations, either genetic and/or environmental, underlie many psychiatric and neurodevelopment disorders. The Walsh lab focuses on gaining an improved understanding of the biological basis of behavior using a multi-level approach to elucidate the molecular and circuit mechanisms underlying motivated social behavior. The goal of our research is to uncover how neural systems govern social interactions and what alterations occur in disease states to inform the development of novel therapeutics or treatment strategies. One of the major focuses of the Walsh lab is on understanding how genetic mutations, as well as experience, lead to circuit adaptations that govern impaired behavior seen in mouse models of autism spectrum disorders (ASD). Our systems level analysis includes: 1) modeling these disorders with well described genetic markers, 2) defining causal relationships between activity within discrete anatomical structures in the brain that are critical to the physiology of the symptom under investigation (e.g. sociability), 3) performing deep characterization of the physiological profiles of these circuits and using that information to target specific receptors or molecules that may not have been considered for the treatment of specific ASD symptoms.
Benhabbour, Rahima WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Pathobiology & Translational Science RESEARCH INTEREST Biomaterials, Drug Delivery, Nanomedicine, Pharmacology	Dr. Benhabbour’s academic research focuses on development of novel tunable delivery platforms and polymer-based devices to treat or prevent a disease. Her work combines the elegance of organic and polymer chemistry with the versatility of engineering and formulation development to design and fabricate efficient and translatable nanocarriers and drug delivery systems for cancer treatment and HIV prevention. Dr. Benhabbour has also Founded her startup company Anelleo, Inc. (AnelleO) in 2016 to develop the first 3D printed intravaginal ring as a platform technology for women’s health. Current technologies in development in Dr. Benhabbour’s Lab include: – 3D Printed intravaginal ring technology: A) Multipurpose prevention technology (MPT) for prevention of HIV/STIs and unplanned pregnancy. – Polymer based ultra-long-acting injectable implant for HIV prevention and treatment. – Combinatory chitosan/cellulose nanocrystals thermoresponsive hydrogel system: A) Sub-Q or intraosseous injectable for treatment of osteoporosis; B) Bio-ink for 3D bioprinting; C) Scaffold for stem cell delivery (e.g. iNSCs for treatment of post-surgical glioblastoma. – Mucoadhesive thin film for treatment of vulvodynia. – Targeted nanoparticles and hydrogel scaffolds for treatment of NSCLC.
Coleman, Leon WEBSITE EMAIL PUBLICATIONS	PHD PROGRAM Neuroscience, Pharmacology RESEARCH INTEREST Behavior, Cancer Biology, Cell Signaling, Drug Discovery, Immunology, Molecular Biology, Neurobiology, Pharmacology, Translational Medicine	The overriding goal of Dr. Coleman’s work is to identify novel treatments for alcohol use disorders (AUD) and associated peripheral disease pathologies. Currently, this includes: the role of neuroimmune Signaling in AUD pathology, the role of alcohol-associated immune dysfunction in associated disease states, and novel molecular and subcellular mediators of immune dysfunction such as extracellular vesicles, and regenerative medicine approaches such as microglial repopulation.

Research Interest: Pharmacology